Proto-oncogene products as target antigens for cancer vaccines (review)

International Journal of Oncology

Volumn 11, Issue 4, 1997, Pages 863-868

  Halpern, Michael ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Proto oncogenes

Indexed keywords

CANCER VACCINE; GENE PRODUCT; ONCOPROTEIN;

AUTOIMMUNITY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN TARGETING; PROTO ONCOGENE; REVIEW; TUMOR CELL; VACCINATION; VACCINE PRODUCTION;

EID: 0030987664     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Kedar E and Klein E: Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Cancer Res 59: 245-294, 1992.
2. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991.
3. Barbacid M: Ras genes. Annu Rev Biochem 56: 779-827, 1987.
4. Bos JL: Ras oncogenes in human cancer. A review. Cancer Res 49: 4682-4689, 1989.
5. Almoquera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 33: 549-554, 1988.
6. Bos JL, Fearon ER, Hamilton SR, Verlaan-deVries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
7. Cheever MA, Chen W, Disis ML, Takahashi M and Peace DJ: T-cell immunity to oncogenic proteins including mutated ras and chimeric BCR-ABL. In: Specific Immunotherapy of Cancer with Vaccines. Bystryn S, Ferrone S, Livingston P (eds). New York Acad Sci NY pp 101-112, 1993.
8. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M and Chen W: Immunity to oncogenic proteins. Immunol Rev 145: 33-59, 1995.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Kieth DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2 proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
10. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierrotti MA and Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49, 1991.
11. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA and Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82: 2617-2623, 1993.
12. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T and Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84: 3158-3165, 1994.
13. Park J, Meislcr AI, and Cartwright CA: c-yes tyrosine kinasc activity in human colon carcinoma. Oncogene 8: 2627-2635, 1993.
14. Peña SV, Melhem MF, Meisler AI and Cartwright CA: Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 108: 117-124, 1995.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
16. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G and Croce C: Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 222: 390-393, 1983.
17. Cesarman E, Dalla-Favera R, Bentley D and Groudine M: Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 238: 1272-1275, 1987.
18. Yu BW, Ichinose I, Bonham MA and Zajac-Kaye M: Somatic mutations in c-myc intron I cluster in discrete domains that define protein binding sequences. J Biol Chem 268: 19586-19592, 1993.
19. Kappler JW, Roehm N and Marrack P: T cell tolerance by clonal elimination in the thymus. Cell 49: 273-280, 1987.
20. MacDonald HR, Schneider R, Lees RK, Howe RC, AchaOrbea H, Festenstein H, Zinkernagel RM and Hengartner H: T-cell receptor V beta use predicts reactivity and tolerance to MIsa-encoded antigens. Nature 332: 40-45, 1988.
21. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994.
22. Nossal GJV: Tolerance and ways to break it. In: Specific Immunotherapy of Cancer with Vaccines. Bystryn S, Ferrone S, Livingston P (eds). New York Acad Sei NY pp34-41, 1993.
23. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A and Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11: 729-766, 1993.
24. Gammon G and Sercarz EE: How some T cells escape tolerance induction. Nature 342: 183-185, 1989.
25. Nanda NK and Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82: 13-17, 1995.
26. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y and Greenberg PD: An evaluation of the potential to use tumorassociated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med 177: 1681-1690, 1993.
27. Roth C, Rochlitz C and Kourilsky P: Immune response against tumors. Adv Immunol 57: 281-351, 1994.
28. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P and Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365, 1994.
29. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, Van den Eynde B, Uyttenhove C, Renauld JC and Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145: 229-250, 1995.
30. Henderson RA and Finn OJ: Human tumor antigens are ready to fly. Adv Immunol 62: 217-256, 1996.
31. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R and Cheever MA: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20, 1994.
32. Peoples GE, Goedegebure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
33. Fisk B, Blevins TL,Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
34. Disis ML, Smith JW, Murphy AE, Chen W and Cheever MA; In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54: 1071-1076, 1994.
35. Dahl AM, Beverley PC and Stauss HJ: A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 157: 239-246, 1996.
36. Halpern MS, England JM, Kopen GC, Christou AA and Taylor RL: Endogenous c-src as a determinant of the tumorigenicity of src oncogenes. Proc Natl Acad Sci USA 93: 824-827, 1996.